Table 3.
Relative abundance of each Gardnerella genomospecies in each group.
| All participants (N=171) | Group cured (N=61) a | Group intermediate (N=36) b | Group failed (N=33) c | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genomospecies | Healthy | BV patients | P valued | Pretreatment | Posttreatment | P valued | Pretreatment | Posttreatment | P valued | Pretreatment | Posttreatment | P valued |
| Relative abundance (%) of each genus, mean (95%CI) | ||||||||||||
| GS01 | 5.20 (0.37-10.02) | 14.7 (11.14-18.26) | <.0001 | 15.22 (9.89-20.54) | 11.03 (5.47-16.59) | .0002 | 12.17 (5.63-18.71) | 12.94 (6.09-19.79) | .3272 | 16.52 (8.84-24.19) | 17.95 (9.41-26.48) | .8878 |
| GS02 | 0.65 (0.14-1.16) | 9.16 (6.98-11.33) | <.0001 | 7.94 (5.54-10.34) | 3.73 (1.13-6.32) | <.0001 | 11.66 (6.00-17.31) | 7.56 (3.18-11.95) | .2112 | 8.64 (4.33-12.95) | 9.04 (4.56-13.53) | .9234 |
| GS03 | 0.54 (-0.16-1.23) | 2.83 (1.89-3.76) | <.0001 | 3.84 (2.30-5.37) | 3.45 (0.77-6.13) | <.0001 | 1.62 (0.37-2.86) | 0.68 (0.10-1.26) | .5614 | 2.30 (0.30-4.30) | 2.16 (0.42-3.89) | .8374 |
| GS05 | 0.02 (0.00-0.03) | 2.17 (1.56-2.77) | <.0001 | 2.35 (1.37-3.33) | 0.52 (0.03-1.01) | .0012 | 1.95 (0.93-2.96) | 1.48 (0.35-2.62) | .5835 | 2.07 (0.84-3.30) | 1.93 (0.84-3.01) | .657 |
| GS07 | 0.05 (-0.05-0.15) | 0.52 (0.16-0.87) | .0053 | 0.42 (0.10-0.74) | 0.00 (0.00-0.00) | .0053 | 0.85 (-0.24-1.93) | 0.03 (0.00-0.05) | .6835 | 0.33 (-0.20-0.87) | 0.62 (-0.05-1.75) | .7967 |
| GS08 | 0.00 (0.00-0.00) | 0.01 (0.00-0.02) | .0189 | 0.02 (0.00-0.03) | 0.00 (0.00-0.00) | <.0001 | 0.02 (-0.02-0.04) | 0.02 (-0.02-0.04) | .2555 | 0.00 (0.00-0.00) | 0.02 (0.00-0.03) | .6641 |
| GS09 | 0.01 (-0.01-0.02) | 0.28 (0.22-0.35) | <.0001 | 0.32 (0.21-0.43) | 0.09 (0.02-0.16) | <.0001 | 0.27 (0.16-0.37) | 0.18 (0.05-0.31) | .0954 | 0.24 (0.11-0.37) | 0.21 (0.10-0.31) | .9843 |
BV, bacterial vaginosis; GS, genomospecies.
a “Group Cured” was defined as patients whose Nugent score were lowered to 0-3 after metronidazole treatment. b “Group Intermediate” was defined as patients whose Nugent score were changed to 4-6 after metronidazole treatment. c “Group Failed” was defined as patients whose Nugent score remained at 7-10 after metronidazole treatment. d Wilcoxon test was used for comparison between these two groups.